How cartilage metabolism keeps joints healthy
Metabolic Regulation of Articular Cartilage and Joint Homeostasis
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11138612
This work explores how a natural cell signal called TGF-β1 helps cartilage cells use sugar to build the materials that keep joints working, with the goal of helping people with osteoarthritis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11138612 on ClinicalTrials.gov |
What this research studies
This project looks at how TGF-β1 controls sugar uptake and metabolic pathways in cartilage cells to support production of key matrix components like hyaluronic acid and glycosaminoglycans. The team measures glucose uptake, glycolysis, and the hexosamine biosynthetic pathway (HBP) and tracks key genes such as Glut1, Gfpt2, and Slc25a1. They use laboratory cell and tissue experiments plus RNA sequencing and mass spectrometry to map how carbon from glucose is used to make UDP-GlcNAc and other building blocks. The goal is to find molecular targets that could be restored or mimicked when TGF-β signaling is reduced in aging or osteoarthritis.
Who could benefit from this research
Good fit: Adults with osteoarthritis or age-related joint degeneration (for example knee or hip OA) would be the most relevant patient group for future applications.
Not a fit: People with primarily inflammatory autoimmune arthritis (like rheumatoid arthritis) or those needing immediate joint replacement surgery may not directly benefit from these metabolic-targeting approaches.
Why it matters
Potential benefit: If successful, this work could point to new drug targets or treatments that restore cartilage repair and slow or prevent progression of osteoarthritis.
How similar studies have performed: Previous studies support a key role for TGF-β signaling and metabolism in cartilage health, but targeting the HBP pathway and the specific transporters identified here is a relatively new approach with limited clinical testing so far.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: O'KEEFE, REGIS J — WASHINGTON UNIVERSITY
- Study coordinator: O'KEEFE, REGIS J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.